Antibody Developability Patents: Who Leads, Where the Gaps Are 2026
Antibody Developability Assessment Patents: Filing Trends and Who Holds the Claim Space
Concentrated but not locked up. the ranked leader holds 132 records and the top 5 combined account for 24.8% of all 1,707 records in scope, leaving most of the field to a long tail of single- and low-count filers. Annual filings climbed from 60 in 2017 to a peak of 225 in 2021, then declined to 179 by 2024 — a 20% drop over that three-year window. Counts for 2025 and 2026 are not yet comparable: publication typically lags filing by around 18 months, so the most recent two years will continue to fill in as later publications post.
- 1BRISTOL MYERS SQUIBB CO132
- 2PFIZER INC100
- 3MASSACHUSETTS INST OF TECH69
- 4NOVARTIS AG62
- 5ATYR PHARM INC61
See the full antibody developability assessment analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on antibody developability patents
What counts as an antibody developability assessment patent?
These are patents and applications claiming methods, assays or compositions used to predict or measure how manufacturable and stable an antibody candidate will be, covering areas such as aggregation propensity, colloidal stability, viscosity at high concentration, charge heterogeneity, hydrophobic patch analysis, forced degradation testing, and chemical liability motif detection. Many are filed as part of a broader antibody or formulation application rather than as a standalone assay patent, which is why classes like A61K and C07K dominate the IPC composition. The dataset behind this page pulls 1,707 such records published between 2015 and mid-2026.
Who holds the most patents in antibody developability assessment?
The ranked assignee list covers 100 companies, with the leading filer holding 132 records against 61 for the fifth-ranked company and 40 for the tenth. The top 5 combined account for 24.8% of all 1,707 records in scope, and the top 10 reach 37.8%, so while there is a clear leader, the majority of filings sit outside the most active ten assignees. Large pharmaceutical and biotech companies dominate the upper ranks rather than specialist analytics vendors.
Is patent filing in this field growing or slowing down?
Filings rose from 60 in 2017 to a peak of 225 in 2021, then eased to 179 by 2024 — a 20% decline over that three-year window, which is the most recent period that can be read reliably. Counts for 2025 and 2026 appear lower still, but that reflects publication lag rather than an actual drop in filing activity, since publication typically trails the underlying filing date by around 18 months. Treat any apparent recent-year decline with that lag in mind.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Antibody Developability Assessment covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.